BioSpace News Archive

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021.

Thermo Fisher Scientific, the world leader in serving science, today announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its mid-year 2021 business and clinical update.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, today announced the acquisition of HBS-102 (formerly CSTI-100),

AbbVie (NYSE: ABBV) today announced that SKYRIZI® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis.

To help combat the COVID-19 pandemic, laboratory supplier Carolina Liquid Chemistries Corp. has launched MyPOCtest.com, a new e-commerce website to help supply medical facilities with rapid tests at the point-of-care.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today successful completion of a series of preclinical experiments requested by the United States Food and Drug Administration (FDA) in order to begin Phase I/II clinical trials.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today reported financial results for the second quarter 2021 and recent business highlights.

GlycoMimetics, Inc. announced that the compensation committee of the Company’s Board of Directors approved the grant on August 3, 2021 of non-qualified stock option awards to purchase an aggregate of 1,647,600 shares of its common stock to Harout Semerjian, the Company’s new President and Chief Executive Officer.

City of Hope, a world-renowned cancer research and treatment center, announced that acclaimed Pacific Shores Medical Group has joined City of Hope.